COMPANY PROFILE // THE 014 REPORT
Kairos Pharma, LTD.
KAPA (NYSE)
Assembled from 1 government source in 3.3 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-04-28 (last 24 months).
- AmberNT 10-K filed on 2025-03-28: notice that a periodic report would be late.
- InfoRegistered business address (2355 WESTWOOD BLVD. #139, LOS ANGELES) is shared with 11 other entities in our records (SEC registrants and IRS-registered organizations).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record; address shared with 11 entities.
Kairos Pharma, LTD. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Los Angeles, CA; listed as KAPA (NYSE).[source] It has filed 33 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-13.[source] Seraphix flags 2 items from these records: 8-K Item 4.01 filed; NT 10-K filed on 2025-03-28.[source]
- red0
- amber2
- info1
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Bhowmick Neil · Chief Scientific Officer (Officer) · latest Form 4 2025-12-30 · filing · LinkedIn search
- Murali Ramachandran · VP of Research and Development (Officer) · latest Form 4 2025-11-26 · filing · LinkedIn search
- Samuelson Doug · Chief Financial Officer (Officer) · latest Form 4 2025-11-26 · filing · LinkedIn search
- Yu John S · CEO and Chairman (Director,Officer,10% owner) · latest Form 4 2025-11-26 · filing · LinkedIn search
- Bae Hyun W. · Director · latest Form 4 2025-12-23 · filing · LinkedIn search
- Keyoung Hansoo Michael · Director · latest Form 4 2025-11-26 · filing · LinkedIn search
- Singhvi Rahul · Director · latest Form 4 2025-11-26 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001962011 | source |
| EIN | 46-2993314 | source |
| California SOS entity | 0003552221-0001-4 | record |
| Business address (SEC) | 2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; <br>Emerging growth company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (12)
- FOMUKONG HEALTH FOUNDATION INC · IRS-registered organization
- WEST LOS ANGELES LACROSSE · IRS-registered organization
- LANGRUM SHANKLE INITIATIVE · IRS-registered organization
- FOUNDATION THINKAGAIN · IRS-registered organization
- IMAGINE1DAY USA INC · IRS-registered organization
- NOTODOGMEAT - USA CORP · IRS-registered organization
- PERCEPTION PROJECT · IRS-registered organization
- AMBITION COLLECTIVE INC · IRS-registered organization
- FROM THE HEART TRIBE · IRS-registered organization
- CAREER SPARKS · IRS-registered organization
- EQUITY ENGINE · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- CODEXIS, INC. · Singhvi Rahul
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-05 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-11-03 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-10-06 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-09-14 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-08-21 filing 8-K items 3.03,5.03,7.01,9.01 · SEC EDGAR
- 2026-08-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-22 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-07-15 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-30 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-04 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-26 filing DEFA14A · SEC EDGAR
- 2026-05-22 filing ARS · SEC EDGAR
- 2026-05-22 filing Proxy statement · SEC EDGAR
- 2026-05-18 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-05-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-11 filing PRE 14A · SEC EDGAR
- 2026-04-01 filing 424B3 · SEC EDGAR
- 2026-04-01 filing 424B3 · SEC EDGAR
- 2026-03-31 filing Annual report (10-K) · SEC EDGAR
- 2026-03-02 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-02-26 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-01-23 filing EFFECT · SEC EDGAR
- 2026-01-21 filing CORRESP · SEC EDGAR
- 2026-01-15 filing UPLOAD · SEC EDGAR
- 2026-01-13 filing S-3 · SEC EDGAR
- 2025-12-23 insider First Form 3/4/5 on record for Bae Hyun W. (Director) · SEC Forms 3/4/5
- 2025-11-26 insider First Form 3/4/5 on record for Murali Ramachandran (VP of Research and Development) · SEC Forms 3/4/5
- 2025-11-26 insider First Form 3/4/5 on record for Samuelson Doug (Chief Financial Officer) · SEC Forms 3/4/5
- 2025-11-26 insider First Form 3/4/5 on record for Yu John S (CEO and Chairman) · SEC Forms 3/4/5
80 earlier entries
- 2025-11-26 insider First Form 3/4/5 on record for Keyoung Hansoo Michael (Director)
- 2025-11-14 filing Quarterly report (10-Q)
- 2025-10-15 officer change 8-K items 5.02,9.01
- 2025-10-07 filing 8-K items 1.01,8.01,9.01
- 2025-09-18 filing 8-K items 8.01,9.01
- 2025-09-11 filing 8-K items 8.01,9.01
- 2025-09-03 filing 8-K items 8.01,9.01
- 2025-08-19 filing 424B3
- 2025-08-12 filing Quarterly report (10-Q)
- 2025-07-28 filing 10-K/A
- 2025-07-15 filing 8-K items 8.01,9.01
- 2025-06-12 filing 8-K items 1.01,5.07,9.01
- 2025-06-03 filing 8-K items 8.01,9.01
- 2025-05-16 filing DEFR14A
- 2025-05-14 filing Quarterly report (10-Q)
- 2025-05-06 filing PRER14A
- 2025-05-01 filing Proxy statement
- 2025-04-30 insider First Form 3/4/5 on record for Singhvi Rahul (Director)
- 2025-04-29 filing 10-K/A
- 2025-04-28 filing 8-K items 4.01,9.01
- 2025-04-25 filing 424B3
- 2025-04-24 filing EFFECT
- 2025-04-24 filing 8-K items 8.01,9.01
- 2025-04-22 filing CORRESP
- 2025-04-22 filing Registration (S-1)
- 2025-04-15 filing Annual report (10-K)
- 2025-04-07 insider First Form 3/4/5 on record for Bhowmick Neil (Chief Scientific Officer)
- 2025-03-28 filing NT 10-K
- 2025-03-20 filing 8-K items 8.01,9.01
- 2025-02-26 filing 8-K items 8.01,9.01
- 2025-02-10 filing DEF 14C
- 2025-02-06 filing 8-K items 8.01,9.01
- 2025-02-05 filing 424B3
- 2025-02-04 filing EFFECT
- 2025-01-31 filing CORRESP
- 2025-01-31 filing UPLOAD
- 2025-01-29 filing PRE 14C
- 2025-01-29 filing Registration (S-1)
- 2025-01-28 filing D
- 2025-01-17 filing 8-K items 1.01,3.02,9.01
- 2025-01-14 filing 8-K items 1.01,3.02,9.01
- 2025-01-06 filing UPLOAD
- 2025-01-03 filing DRS
- 2024-12-13 officer change 8-K items 5.02,9.01
- 2024-11-19 filing 8-K items 7.01,9.01
- 2024-11-14 filing Quarterly report (10-Q)
- 2024-10-10 filing 8-K items 8.01,9.01
- 2024-10-04 filing 8-K items 1.01,9.01
- 2024-09-27 filing S-8
- 2024-09-27 filing 8-K items 1.01,9.01
- 2024-09-24 filing 8-K items 1.01,8.01,9.01
- 2024-09-17 filing 8-K items 1.01,7.01,9.01
- 2024-09-17 filing 424B4
- 2024-09-16 filing EFFECT
- 2024-09-13 filing CORRESP
- 2024-09-13 filing CORRESP
- 2024-09-13 filing CORRESP
- 2024-09-12 filing CERT
- 2024-09-12 filing 8-A12B
- 2024-09-09 filing CORRESP
- 2024-09-09 filing CORRESP
- 2024-08-16 filing S-1/A
- 2024-06-04 filing S-1/A
- 2024-06-03 filing CORRESP
- 2024-05-24 filing S-1/A
- 2024-05-20 filing S-1/A
- 2024-05-13 filing S-1/A
- 2024-05-01 filing S-1/A
- 2024-02-14 filing S-1/A
- 2023-12-07 filing S-1/A
- 2023-09-29 filing Registration (S-1)
- 2023-09-18 filing DRS/A
- 2023-09-15 filing DRSLTR
- 2023-07-06 filing UPLOAD
- 2023-06-28 filing DRSLTR
- 2023-06-28 filing DRS/A
- 2023-06-28 filing DRS/A
- 2023-04-27 filing D
- 2023-04-25 filing UPLOAD
- 2023-03-29 filing DRS
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 7 days) 10-Q filed
- 2026-11-05 (within 30 days) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-03 (within 30 days) 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-06 (older) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-09-14 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-21 (older) 8-K filed: Item 3.03 rights of holders modified; Item 5.03 charter or bylaw amendment; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-12 (older) 10-Q filed
- 2026-07-22 (older) 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NYSE:KAPA The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1962011 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | KAPA / NYSE | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 462993314 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001962011 | SEC EDGAR / IRS |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$5,447,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 09:55 UTC | Report an error |
| Total assets (at 2025-12-31) | $6,540,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 09:55 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $6,341,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 09:55 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $4,491,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 09:55 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 09:55 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 09:55 UTC | Report an error |
| State of incorporation | DE | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 09:55 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 09:55 UTC | Report an error |
| Business address | 2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 09:55 UTC | Report an error |
| Exchanges | NYSE | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-20 09:55 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$3,441,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 09:55 UTC | Report an error |
| Form D total offering amount (D filed 2025-01-28) | $8,750,000 | 2025-01-28 | D | as filed | 2026-11-20 09:55 UTC | Report an error |
| Form D total amount sold (D filed 2025-01-28) | $3,497,500 | 2025-01-28 | D | as filed | 2026-11-20 09:55 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2025-01-28 | D | as filed | 2026-11-20 09:55 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2025-01-28 | D | as filed | 2026-11-20 09:55 UTC | Report an error |
| Form D date of first sale | 2025-01-16 | 2025-01-28 | D | as filed | 2026-11-20 09:55 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001493152-26-051822
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$1,984,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001493152-26-051822 | 2026-11-20 09:55 UTC | Report an error |
| Cash and cash equivalents | $3,125,000 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001493152-26-051822 | 2026-11-20 09:55 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 10-Q filed
- 2026-11-05 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-11-03 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-10-06 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-09-14 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-21 Filing 8-K filed: Item 3.03 rights of holders modified; Item 5.03 charter or bylaw amendment; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-08-12 Filing 10-Q filed
- 2026-07-22 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-15 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-30 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-06-04 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-26 Filing DEFA14A filed
- 2026-05-22 Filing ARS filed
- 2026-05-22 Filing DEF 14A filed
- 2026-05-18 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-05-13 Filing 10-Q filed
- 2026-05-11 Filing PRE 14A filed
- 2026-04-01 Filing 424B3 filed
- 2026-04-01 Filing 424B3 filed
- 2026-03-31 Filing 10-K filed
- 2026-03-02 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-02-26 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-01-23 Filing EFFECT filed
- 2026-01-21 Filing CORRESP filed
- 2026-01-15 Filing UPLOAD filed
8-K item text, as filed (excerpts)
- 2026-11-03 8-K Item 1.01, Entry into a Material Definitive
Agreement. Amendments to Purchase Agreement As previously disclosed in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2024, Kairos Pharma, Ltd. (the “Company”) entered into a purchase agreement with Helena Global Investment Opportunities I Ltd. (“Helena”), dated November 12, 2024 (the “Purchase Agreement”), pursuant to which the Company established an equity line of credit with Helena (the “ELOC”). On February 4, 2026, the Company and Helena executed an amendment to the Purchase Agreement (the “First Amendment”) pursuant to which the purchase price was adjusted to 97% of the average daily VWAP during the Pricing Period (as… the 8-K · retrieved 2026-11-20 09:55 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
California business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchKAIROS PHARMA LTD · exact legal name · sx:cabiz:la:0003552221-0001-4 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchKairos Pharma · exact name match to 'Kairos Pharma, LTD.' (no other entity shares the name) · sx:ctgov:hb7eca5394b3a2864 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1962011.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001962011. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.